Published Papers

  • Perez AL, Bachrach E, Illigens BM, Jun SJ, Bagden E, Steffen L, Flint A, McGowan FX, Del Nido P, Montecino-Rodriguez E, Tidball JG, Kunkel LM. CXCR4 enhances engraftment of muscle progenitor cells. Muscle Nerve. 2009 Oct;40(4):562-72.
  • Kunkel LM, Bachrach E, Bennett R, Guyon J and Steffen L. Diagnosis and Cell-Based Therapy for Duchenne Muscular Dystrophy in Humans, Mice and Zebrafish. Journal of Human Genetics (2006):1-10. DOI 10.1007/s10038-006-0374-9.Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3581-6.
  • Dreja H, Gros L, Villard S, Bachrach E, Oates A, Granier C, Chardes T, Mani JC, Piechaczyk M and Pelegrin M. Monoclonal antibody 667 recognizes the variable region A motif of the ecotropic retrovirus CasBrE envelope glycoprotein and inhibits Env binding to the viral receptor. Journal of Virology October 2003; 77(20) :10984-93.
  • Karavanas G, Marin M, Bachrach E, Papavassiliou G and Piechaczyk M. The insertion of an anti-MHC I ScFv into the N-terminus of an ecotropic MLV glycoprotein does not alter its fusiogenic potential on murine cells. Virus Res 2002 Feb 26;83(1-2):57-69.
  • Marin M, Pelegrin-Zurilla M, Bachrach E, Noël D, Brockly F and Piechaczyk M. Antiviral activity of an intracellularly-expressed single-chain antibody fragment directed against the MuLV capsid protein. Human Gene Therapy 2000 11, p.389-401.
  • Pelegrin M, Noël D, Marin M, Bachrach E, Saller R, Salmons B and Piechaczyk M. In vivo production of therapeutic antibodies by engineered cells for immunotherapy of cancer and viral diseases. 1998 Gene Ther. Molec. Biol. 3 1-9.

Book Chapters

  • Bachrach E, Perez AL and Kunkel LM. Muscular Dystrophies. In press, Chapter 16-06, Gellis and Kagan’s Current Pediatric Therapy 18th Edition, Elsevier Inc., October 2005.
  • Bachrach E, Duch M, Pelegrin M, Pedersen FS and Piechaczyk M. In vivo infection of mice by replication-competent MLV-based retroviral vectors. Methods Mol. Med. 2003 ; 76 :343-52.
  • Pelegrin M., Bachrach E and Piechaczyk M. Engineered antibodies in gene therapy. Therapeutic Antibody Technology, Ed Zenon St.eplewski and Thomas Kieber-Emmons Marcel Dekker, Inc., New York, August 2000.